Synthaverse S.A. (SVE.WA)
PLN 4.46
(-0.22%)
PLN 4.46
(-0.22%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 8.64 Million PLN | -12.14% |
| 2022 | 9.84 Million PLN | 36.85% |
| 2021 | 7.19 Million PLN | 21.36% |
| 2020 | 5.92 Million PLN | 3.64% |
| 2019 | 5.71 Million PLN | 116.13% |
| 2018 | -35.43 Million PLN | -830.1% |
| 2017 | 4.85 Million PLN | 117.47% |
| 2016 | -27.79 Million PLN | 16.42% |
| 2015 | -33.25 Million PLN | -1197.26% |
| 2014 | 3.03 Million PLN | -40.54% |
| 2013 | 5.09 Million PLN | 185.05% |
| 2012 | -5.99 Million PLN | -318.82% |
| 2011 | 2.73 Million PLN | -41.65% |
| 2010 | 4.69 Million PLN | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | 1.02 Million PLN | -83.54% |
| 2024 Q2 | 2.75 Million PLN | 170.49% |
| 2023 Q4 | 6.19 Million PLN | 311.03% |
| 2023 Q3 | -2.93 Million PLN | -171.95% |
| 2023 Q2 | 4.08 Million PLN | 213.04% |
| 2023 FY | 8.64 Million PLN | -12.14% |
| 2023 Q1 | 1.3 Million PLN | -70.15% |
| 2022 Q4 | 4.36 Million PLN | 111.83% |
| 2022 Q3 | 2.06 Million PLN | -47.2% |
| 2022 Q2 | 3.9 Million PLN | 892.09% |
| 2022 Q1 | -493 Thousand PLN | -111.56% |
| 2022 FY | 9.84 Million PLN | 36.85% |
| 2021 Q1 | -817 Thousand PLN | -126.67% |
| 2021 Q2 | 4.13 Million PLN | 606.0% |
| 2021 Q3 | -388 Thousand PLN | -109.39% |
| 2021 FY | 7.19 Million PLN | 21.36% |
| 2021 Q4 | 4.26 Million PLN | 1198.97% |
| 2020 Q4 | 3.06 Million PLN | 390.87% |
| 2020 FY | 5.92 Million PLN | 3.64% |
| 2020 Q1 | 2.27 Million PLN | -0.48% |
| 2020 Q2 | -37 Thousand PLN | -101.62% |
| 2020 Q3 | 624 Thousand PLN | 1786.49% |
| 2019 FY | 5.71 Million PLN | 116.13% |
| 2019 Q1 | 991 Thousand PLN | 102.78% |
| 2019 Q2 | 992 Thousand PLN | 0.1% |
| 2019 Q3 | 1.44 Million PLN | 45.77% |
| 2019 Q4 | 2.28 Million PLN | 58.23% |
| 2018 Q4 | -35.61 Million PLN | -27939.37% |
| 2018 Q3 | -127 Thousand PLN | -425.64% |
| 2018 Q2 | 39 Thousand PLN | -84.94% |
| 2018 Q1 | 259 Thousand PLN | -98.61% |
| 2018 FY | -35.43 Million PLN | -830.1% |
| 2017 Q3 | 1 Million PLN | 107.24% |
| 2017 FY | 4.85 Million PLN | 117.47% |
| 2017 Q4 | 18.58 Million PLN | 1748.76% |
| 2017 Q2 | -13.88 Million PLN | -2370.64% |
| 2017 Q1 | -562 Thousand PLN | 96.77% |
| 2016 Q3 | -2.32 Million PLN | 70.87% |
| 2016 Q4 | -17.41 Million PLN | -648.3% |
| 2016 FY | -27.79 Million PLN | 16.42% |
| 2016 Q1 | -63 Thousand PLN | 99.79% |
| 2016 Q2 | -7.98 Million PLN | -12577.78% |
| 2015 Q2 | 220 Thousand PLN | 112.55% |
| 2015 Q3 | -1.59 Million PLN | -824.09% |
| 2015 FY | -33.25 Million PLN | -1197.26% |
| 2015 Q4 | -30.12 Million PLN | -1791.02% |
| 2015 Q1 | -1.75 Million PLN | -156.07% |
| 2014 Q3 | -1.1 Million PLN | -256.8% |
| 2014 FY | 3.03 Million PLN | -40.54% |
| 2014 Q1 | 303.98 Thousand PLN | -74.3% |
| 2014 Q2 | 704.37 Thousand PLN | 131.72% |
| 2014 Q4 | 3.12 Million PLN | 383.07% |
| 2013 Q4 | 1.18 Million PLN | -35.69% |
| 2013 Q2 | 506.47 Thousand PLN | -67.69% |
| 2013 Q3 | 1.83 Million PLN | 263.17% |
| 2013 Q1 | 1.56 Million PLN | 131.74% |
| 2013 FY | 5.09 Million PLN | 185.05% |
| 2012 Q4 | -4.93 Million PLN | -105.19% |
| 2012 FY | -5.99 Million PLN | -318.82% |
| 2012 Q2 | 436.74 Thousand PLN | -52.38% |
| 2012 Q3 | -2.4 Million PLN | -651.13% |
| 2012 Q1 | 917.22 Thousand PLN | 0.0% |
| 2011 FY | 2.73 Million PLN | -41.65% |
| 2010 FY | 4.69 Million PLN | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Bioceltix S.A. | -15.81 Million PLN | 154.66% |
| BIOTON S.A. | 15.29 Million PLN | 43.465% |
| Captor Therapeutics Spolka Akcyjna | -73.01 Million PLN | 111.843% |
| Mabion S.A. | 55.06 Million PLN | 84.296% |
| Molecure S.A. | -22.1 Million PLN | 139.12% |
| NanoGroup S.A. | -7.9 Million PLN | 209.429% |
| Pharmena S.A. | 34.87 Million PLN | 75.203% |
| Poltreg S.A. | -16.86 Million PLN | 151.281% |
| Pure Biologics Spólka Akcyjna | -31.71 Million PLN | 127.262% |
| Ryvu Therapeutics S.A. | -100.94 Million PLN | 108.566% |
| Urteste S.A. | -6.44 Million PLN | 234.124% |